Enhancement of the t-cell armamentarium as a cell-based therapyfor prostate cancer

Cancer Research

Volumn 74, Issue 13, 2014, Pages 3390-3395

  Brennen, W Nathaniel ^a,b   Drake, Charles G ^b,c   Isaacs, John T ^a,b,c  

^a Chemical Therapeutics Program   (United States)

^b Department of Oncology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTOXIN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL BASED VECTOR; CELL THERAPY; GENE DELIVERY SYSTEM; GENE VECTOR; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT;

ADOPTIVE TRANSFER; CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84903974286     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0249     Document Type: Review

References (30)

1. Drake CG. Update on prostate cancer vaccines. Cancer J 2011;17: 294-9.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
3. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37.
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
5. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
6. Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 2012;1:172-8.
7. Drake CG. Combination immunotherapy approaches. Ann Oncol 2012;23 Suppl 8:viii41-6.
8. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol 2012;24:633-9.
9. Kerkar SP. "Model T" cells: a time-tested vehicle for gene therapy. Front Immunol 2013;4:304.
10. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-93.
11. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215.
12. McClinton S, Miller ID, Eremin O. An immunohistochemical characterisation of the inflammatory cell infiltrate in benign and malignant prostatic disease. Br J Cancer 1990;61:400-3.
13. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8φ Foxp3φ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-58.
14. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8φ T lymphocytes are oligoclonal and PD-1φ. Prostate 2009;69:1694-703.
15. Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting Edge: Tumor-specific CD8φ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 2009;183:4848-52.
16. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-8.
17. Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, et al. Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. J Immunol 2012; 189:3936-46.
18. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98.
19. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
20. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31:71-5.
21. Morgan RA, Yang JC, Kitano M, Dudley ME, LaurencotCM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
22. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
23. Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation antiprostate specific membrane antigen designer T Cells for prostate cancer immunotherapy. Prostate 2014;74:286-96.
24. Rossig C. Extending the chimeric receptor-based T-cell targeting strategy to solid tumors. Oncoimmunology 2013;2:e26091.
25. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99: 376-85.
26. Denmeade SR, Isaacs JT. Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget 2012;3:666-7.
27. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, et al. Engineering a prostate-specific membrane antigenactivated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012;4:140ra86.
28. Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747-54.
29. Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, et al. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis 2013;16: 123-31, S1.
30. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:3621-30.